Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVID-2: Long-Term Extension Study of Mirikizumab in Crohn's Disease
NCT04232553Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
A Phase 3 trial of mirikizumab in Crohn's disease, sponsored by Eli Lilly and Company. Started Jun 2020; status: active, not recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04232553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232553.